AbCellera Biologics Inc (ABCL)
3.735
-0.16
(-4.23%)
USD |
NASDAQ |
Apr 25, 10:38
AbCellera Biologics Total Liabilities (Quarterly): 335.78M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 335.78M |
| September 30, 2023 | 329.42M |
| June 30, 2023 | 342.34M |
| March 31, 2023 | 289.42M |
| December 31, 2022 | 307.63M |
| September 30, 2022 | 302.24M |
| June 30, 2022 | 380.93M |
| March 31, 2022 | 384.78M |
| Date | Value |
|---|---|
| December 31, 2021 | 292.84M |
| September 30, 2021 | 219.34M |
| June 30, 2021 | 184.18M |
| March 31, 2021 | 171.40M |
| December 31, 2020 | 175.03M |
| September 30, 2020 | 53.15M |
| December 31, 2019 | 13.24M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
13.24M
Minimum
Dec 2019
384.78M
Maximum
Mar 2022
252.11M
Average
292.84M
Median
Dec 2021
Total Liabilities (Quarterly) Benchmarks
| Acasti Pharma Inc | 11.50M |
| Aurinia Pharmaceuticals Inc | 170.11M |
| Edesa Biotech Inc | 1.987M |
| Lexaria Bioscience Corp | 0.2042M |
| InMed Pharmaceuticals Inc | 2.483M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.488B |
| Shareholders Equity (Quarterly) | 1.152B |
| Current Ratio | 7.327 |